The alpha glucosidase inhibitors market size has grown strongly in recent years. It will grow from $4.84 billion in 2025 to $5.19 billion in 2026 at a compound annual growth rate (CAGR) of 7.2%. The growth in the historic period can be attributed to rising prevalence of type 2 diabetes, increasing geriatric population, government initiatives for diabetes awareness, limited availability of advanced therapies in emerging markets, growth in research on alpha-glucosidase inhibitors.
The alpha glucosidase inhibitors market size is expected to see strong growth in the next few years. It will grow to $7.05 billion in 2030 at a compound annual growth rate (CAGR) of 8%. The growth in the forecast period can be attributed to technological advancements in drug formulation, rising adoption of combination therapies, increased investment in digital health monitoring, expansion of online pharmacy channels, development of precision medicine solutions. Major trends in the forecast period include personalized diabetes management solutions, development of low-glycemic diet integrated therapies, increased focus on hypoglycemia-safe medications, growth of combination therapy approaches, expansion of patient-centric digital health platforms.
Rising diabetes prevalence globally is expected to propel the growth of the alpha-glucosidase inhibitors market going forward. Diabetes is a long-term metabolic condition marked by high blood glucose (also known as blood sugar) levels, which can seriously harm the heart, blood vessels, eyes, kidneys, and nerves over time. Alpha-glucosidase inhibitors prevent carbohydrate absorption from the small intestine, which inhibits the rise in postprandial blood glucose concentrations and helps control diabetes. For instance, in June 2024, according to the National Health Service, a UK-based government department, in 2023, the NHS identified over half a million (549,000) additional individuals in England at risk of developing type 2 diabetes, bringing the total number of people with non-diabetic hyperglycemia, or pre-diabetes, registered with a GP to 3,615,330. This represents a significant increase compared to 3,065,825 in 2022, highlighting a rise of nearly 20%. Therefore, rising diabetes prevalence globally is driving the growth of the alpha-glucosidase inhibitors market.
Major companies operating in the type 2 diabetes market are focusing on developing innovative therapies to improve glycemic control and patient outcomes. SGLT2 inhibitors work by promoting glucose excretion through urine, helping reduce blood sugar levels in patients with type 2 diabetes. For instance, in January 2023, TheracosBio, a US-based pharmaceutical company, received approval from the U.S. Food and Drug Administration (FDA) for Brenzavvy (bexagliflozin) to treat adults with type 2 diabetes. Brenzavvy is a unique oral inhibitor of sodium-glucose cotransporter 2 (SGLT2). It is suggested as a supplement to diet and exercise to help people with type 2 diabetes better regulate their blood sugar levels by inducing the kidneys to excrete sugar through urine.
In April 2023, Sanofi S.A., a France-based pharmaceutical company acquired Provention Bio Inc. for an undisclosed amount. With this acquisition, Sanofi aims to expand its diabetes drug portfolio with TZIELD (teplizumab-mzwv), an innovative, fully owned, first-in-class therapy in type 1 diabetes. Provention Bio Inc. is a US-based company that develops diabetes drugs.
Major companies operating in the alpha glucosidase inhibitors market are Bayer AG, Merck & Co., Alkem Laboratories Ltd., Cipla Limited, Dr. Reddy's Laboratories Ltd., Emcure Pharmaceuticals Ltd., Lupin Ltd., Novartis AG, Sanofi SA, Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company, Torrent Pharmaceuticals Ltd., Unichem Laboratories Ltd., Pfizer Inc., Boehringer Ingelheim International GmbH, AstraZeneca PLC, Mitsubishi Tanabe Pharma Corporation, Eli Lilly and Company, Johnson & Johnson, Bristol-Myers Squibb, Teva Pharmaceutical Industries Ltd., Hanmi Pharmaceuticals Co. Ltd., Eisai Co. Ltd., Biocon Limited, Cadila Pharmaceuticals Ltd.
North America was the largest region in the alpha glucosidase inhibitors market in 2025. Middle-East is expected to be the fastest-growing region in the forecast period. The regions covered in the alpha glucosidase inhibitors market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the alpha glucosidase inhibitors market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs have influenced the alpha-glucosidase inhibitors market by increasing import costs for active pharmaceutical ingredients and finished drugs, particularly affecting regions like North America and Europe that rely on international suppliers. The price adjustments have impacted segments such as hospital and retail pharmacies, while prompting local manufacturers to enhance domestic production. Despite cost pressures, tariffs may encourage innovation and investment in localized manufacturing capacities, potentially improving supply chain resilience and reducing long-term dependency on imports.
The alpha glucosidase inhibitors market research report is one of a series of new reports that provides alpha glucosidase inhibitors market statistics, including alpha glucosidase inhibitors industry global market size, regional shares, competitors with a alpha glucosidase inhibitors market share, detailed alpha glucosidase inhibitors market segments, market trends and opportunities, and any further data you may need to thrive in the alpha glucosidase inhibitors industry. This alpha glucosidase inhibitors market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Alpha-glucosidase inhibitors are a category of antidiabetic medications that reduce the intestine’s ability to absorb carbohydrates, thereby helping to prevent the progression of type 2 diabetes mellitus in individuals with impaired glucose tolerance. These drugs are particularly beneficial for people who are at risk of hypoglycemia or lactic acidosis.
The main indications for alpha-glucosidase inhibitors include dumping syndrome and type 2 diabetes. Dumping syndrome is characterized by a group of symptoms caused by rapid gastric emptying after meals, where food moves too quickly from the stomach to the duodenum, leading to a rapid rise in blood sugar levels. In such cases, alpha-glucosidase inhibitors are used to slow carbohydrate digestion in the gut, thereby lowering postprandial peak blood glucose levels. The key drug classes include acarbose, miglitol, and voglibose, which inhibit enzymes such as glucoamylase, isomaltase, maltase, and sucrase, and are distributed through online pharmacies, retail pharmacies, and hospital pharmacies.
The alpha-glucosidase inhibitors market consists of sales of glucobay and triazolo quinazolines. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The alpha glucosidase inhibitors market size is expected to see strong growth in the next few years. It will grow to $7.05 billion in 2030 at a compound annual growth rate (CAGR) of 8%. The growth in the forecast period can be attributed to technological advancements in drug formulation, rising adoption of combination therapies, increased investment in digital health monitoring, expansion of online pharmacy channels, development of precision medicine solutions. Major trends in the forecast period include personalized diabetes management solutions, development of low-glycemic diet integrated therapies, increased focus on hypoglycemia-safe medications, growth of combination therapy approaches, expansion of patient-centric digital health platforms.
Rising diabetes prevalence globally is expected to propel the growth of the alpha-glucosidase inhibitors market going forward. Diabetes is a long-term metabolic condition marked by high blood glucose (also known as blood sugar) levels, which can seriously harm the heart, blood vessels, eyes, kidneys, and nerves over time. Alpha-glucosidase inhibitors prevent carbohydrate absorption from the small intestine, which inhibits the rise in postprandial blood glucose concentrations and helps control diabetes. For instance, in June 2024, according to the National Health Service, a UK-based government department, in 2023, the NHS identified over half a million (549,000) additional individuals in England at risk of developing type 2 diabetes, bringing the total number of people with non-diabetic hyperglycemia, or pre-diabetes, registered with a GP to 3,615,330. This represents a significant increase compared to 3,065,825 in 2022, highlighting a rise of nearly 20%. Therefore, rising diabetes prevalence globally is driving the growth of the alpha-glucosidase inhibitors market.
Major companies operating in the type 2 diabetes market are focusing on developing innovative therapies to improve glycemic control and patient outcomes. SGLT2 inhibitors work by promoting glucose excretion through urine, helping reduce blood sugar levels in patients with type 2 diabetes. For instance, in January 2023, TheracosBio, a US-based pharmaceutical company, received approval from the U.S. Food and Drug Administration (FDA) for Brenzavvy (bexagliflozin) to treat adults with type 2 diabetes. Brenzavvy is a unique oral inhibitor of sodium-glucose cotransporter 2 (SGLT2). It is suggested as a supplement to diet and exercise to help people with type 2 diabetes better regulate their blood sugar levels by inducing the kidneys to excrete sugar through urine.
In April 2023, Sanofi S.A., a France-based pharmaceutical company acquired Provention Bio Inc. for an undisclosed amount. With this acquisition, Sanofi aims to expand its diabetes drug portfolio with TZIELD (teplizumab-mzwv), an innovative, fully owned, first-in-class therapy in type 1 diabetes. Provention Bio Inc. is a US-based company that develops diabetes drugs.
Major companies operating in the alpha glucosidase inhibitors market are Bayer AG, Merck & Co., Alkem Laboratories Ltd., Cipla Limited, Dr. Reddy's Laboratories Ltd., Emcure Pharmaceuticals Ltd., Lupin Ltd., Novartis AG, Sanofi SA, Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company, Torrent Pharmaceuticals Ltd., Unichem Laboratories Ltd., Pfizer Inc., Boehringer Ingelheim International GmbH, AstraZeneca PLC, Mitsubishi Tanabe Pharma Corporation, Eli Lilly and Company, Johnson & Johnson, Bristol-Myers Squibb, Teva Pharmaceutical Industries Ltd., Hanmi Pharmaceuticals Co. Ltd., Eisai Co. Ltd., Biocon Limited, Cadila Pharmaceuticals Ltd.
North America was the largest region in the alpha glucosidase inhibitors market in 2025. Middle-East is expected to be the fastest-growing region in the forecast period. The regions covered in the alpha glucosidase inhibitors market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the alpha glucosidase inhibitors market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs have influenced the alpha-glucosidase inhibitors market by increasing import costs for active pharmaceutical ingredients and finished drugs, particularly affecting regions like North America and Europe that rely on international suppliers. The price adjustments have impacted segments such as hospital and retail pharmacies, while prompting local manufacturers to enhance domestic production. Despite cost pressures, tariffs may encourage innovation and investment in localized manufacturing capacities, potentially improving supply chain resilience and reducing long-term dependency on imports.
The alpha glucosidase inhibitors market research report is one of a series of new reports that provides alpha glucosidase inhibitors market statistics, including alpha glucosidase inhibitors industry global market size, regional shares, competitors with a alpha glucosidase inhibitors market share, detailed alpha glucosidase inhibitors market segments, market trends and opportunities, and any further data you may need to thrive in the alpha glucosidase inhibitors industry. This alpha glucosidase inhibitors market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Alpha-glucosidase inhibitors are a category of antidiabetic medications that reduce the intestine’s ability to absorb carbohydrates, thereby helping to prevent the progression of type 2 diabetes mellitus in individuals with impaired glucose tolerance. These drugs are particularly beneficial for people who are at risk of hypoglycemia or lactic acidosis.
The main indications for alpha-glucosidase inhibitors include dumping syndrome and type 2 diabetes. Dumping syndrome is characterized by a group of symptoms caused by rapid gastric emptying after meals, where food moves too quickly from the stomach to the duodenum, leading to a rapid rise in blood sugar levels. In such cases, alpha-glucosidase inhibitors are used to slow carbohydrate digestion in the gut, thereby lowering postprandial peak blood glucose levels. The key drug classes include acarbose, miglitol, and voglibose, which inhibit enzymes such as glucoamylase, isomaltase, maltase, and sucrase, and are distributed through online pharmacies, retail pharmacies, and hospital pharmacies.
The alpha-glucosidase inhibitors market consists of sales of glucobay and triazolo quinazolines. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Alpha Glucosidase Inhibitors Market Characteristics
3. Alpha Glucosidase Inhibitors Market Supply Chain Analysis
4. Global Alpha Glucosidase Inhibitors Market Trends and Strategies
5. Alpha Glucosidase Inhibitors Market Analysis of End Use Industries
7. Global Alpha Glucosidase Inhibitors Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Alpha Glucosidase Inhibitors Total Addressable Market (TAM) Analysis for the Market
9. Alpha Glucosidase Inhibitors Market Segmentation
10. Alpha Glucosidase Inhibitors Market Regional and Country Analysis
11. Asia-Pacific Alpha Glucosidase Inhibitors Market
12. China Alpha Glucosidase Inhibitors Market
13. India Alpha Glucosidase Inhibitors Market
14. Japan Alpha Glucosidase Inhibitors Market
15. Australia Alpha Glucosidase Inhibitors Market
16. Indonesia Alpha Glucosidase Inhibitors Market
17. South Korea Alpha Glucosidase Inhibitors Market
18. Taiwan Alpha Glucosidase Inhibitors Market
19. South East Asia Alpha Glucosidase Inhibitors Market
20. Western Europe Alpha Glucosidase Inhibitors Market
21. UK Alpha Glucosidase Inhibitors Market
22. Germany Alpha Glucosidase Inhibitors Market
23. France Alpha Glucosidase Inhibitors Market
24. Italy Alpha Glucosidase Inhibitors Market
25. Spain Alpha Glucosidase Inhibitors Market
26. Eastern Europe Alpha Glucosidase Inhibitors Market
27. Russia Alpha Glucosidase Inhibitors Market
28. North America Alpha Glucosidase Inhibitors Market
29. USA Alpha Glucosidase Inhibitors Market
30. Canada Alpha Glucosidase Inhibitors Market
31. South America Alpha Glucosidase Inhibitors Market
32. Brazil Alpha Glucosidase Inhibitors Market
33. Middle East Alpha Glucosidase Inhibitors Market
34. Africa Alpha Glucosidase Inhibitors Market
36. Alpha Glucosidase Inhibitors Market Competitive Landscape and Company Profiles
37. Alpha Glucosidase Inhibitors Market Other Major and Innovative Companies
40. Alpha Glucosidase Inhibitors Market High Potential Countries, Segments and Strategies
41. Appendix
Executive Summary
Alpha Glucosidase Inhibitors Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses alpha glucosidase inhibitors market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for alpha glucosidase inhibitors? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The alpha glucosidase inhibitors market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Type: Dumping Syndrome; Type 2 Diabetes2) By Drug Class: Acarbose; Miglitol; Voglibose
3) By Constituent: Glucoamylase; Isomaltase; Maltase; Sucrase
4) By Distribution Channel: Online Pharmacies; Retail Pharmacies; Hospital Pharmacies
Subsegments:
1) By Dumping Syndrome: Post-Gastric Surgery Management; Symptomatic Treatment2) By Type 2 Diabetes: Monotherapy; Combination Therapy
Companies Mentioned: Bayer AG; Merck & Co.; Alkem Laboratories Ltd.; Cipla Limited; Dr. Reddy's Laboratories Ltd.; Emcure Pharmaceuticals Ltd.; Lupin Ltd.; Novartis AG; Sanofi SA; Sun Pharmaceutical Industries Ltd.; Takeda Pharmaceutical Company; Torrent Pharmaceuticals Ltd.; Unichem Laboratories Ltd.; Pfizer Inc.; Boehringer Ingelheim International GmbH; AstraZeneca PLC; Mitsubishi Tanabe Pharma Corporation; Eli Lilly and Company; Johnson & Johnson; Bristol-Myers Squibb; Teva Pharmaceutical Industries Ltd.; Hanmi Pharmaceuticals Co. Ltd.; Eisai Co. Ltd.; Biocon Limited; Cadila Pharmaceuticals Ltd
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Alpha Glucosidase Inhibitors market report include:- Bayer AG
- Merck & Co.
- Alkem Laboratories Ltd.
- Cipla Limited
- Dr. Reddy's Laboratories Ltd.
- Emcure Pharmaceuticals Ltd.
- Lupin Ltd.
- Novartis AG
- Sanofi SA
- Sun Pharmaceutical Industries Ltd.
- Takeda Pharmaceutical Company
- Torrent Pharmaceuticals Ltd.
- Unichem Laboratories Ltd.
- Pfizer Inc.
- Boehringer Ingelheim International GmbH
- AstraZeneca PLC
- Mitsubishi Tanabe Pharma Corporation
- Eli Lilly and Company
- Johnson & Johnson
- Bristol-Myers Squibb
- Teva Pharmaceutical Industries Ltd.
- Hanmi Pharmaceuticals Co. Ltd.
- Eisai Co. Ltd.
- Biocon Limited
- Cadila Pharmaceuticals Ltd
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 5.19 Billion |
| Forecasted Market Value ( USD | $ 7.05 Billion |
| Compound Annual Growth Rate | 8.0% |
| Regions Covered | Global |
| No. of Companies Mentioned | 26 |
